After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent

A coalition of unions, consumer groups, and public interest organizations has written to Lina Khan, Chair of the Federal Trade Commission (FTC), voicing strong opposition to Novo Holdings’ proposed $16.5 billion acquisition of Catalent Inc. (NYSE:CTLT).

The groups argue that the deal, which would unite the Danish pharmaceutical giant and dominant player in GLP-1 drug development, Novo Nordisk A/S (NYSE:NVO), with Catalent, a leading global contract development and manufacturing organization (CDMO), could harm competition in critical areas such as diabetes, obesity treatments, and gene therapies.

Also Read: Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From ...